MK-8669-050
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-8669-050, covering 2015-01-21 to 2015-01-21. Get the full timeline:
Most recent: Clinical Trial Update: The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050) [Phase 1]